Santaris Can't Skirt Isis Suit Over Drug Development Deals

Law360, New York (September 20, 2012, 5:46 PM EDT) -- A California federal judge on Wednesday refused to let Santaris Pharma A/S Corp. off the hook in Isis Pharmaceuticals Inc.'s infringement suit accusing its competitor of leveraging Isis' patented gapmer antisense drug development platform to sign multimillion-dollar deals with industry giants.

U.S. District Judge Barry T. Moskowitz denied Sanrtis’ summary judgment motion without prejudice, saying the company has not convinced him its conduct falls under a federal safe harbor statute.

“The court finds that the facts introduced by Santaris by way of the declaration of one...
To view the full article, register now.